Elevated plasma fibrinogen levels in patients with essential hypertension are related to vascular complications

International Angiology

Volumn 22, Issue 1, 2003, Pages 72-78

  Lechi, C ^a   Gaino, S ^a   Zuliani, V ^a   Tommasoli, R M ^a   Faccini, G ^a   Fasson, R ^a   Arcaro, G ^a   Lechi, A ^a   Minuz, P ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Coronary arteriosclerosis; Fibrinogen; Hypertension, physiopathology; Vascular diseases

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HOMOCYSTEINE;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE REGRESSION; RETINA BLOOD VESSEL; RISK ASSESSMENT; STRATIFICATION; TARGET ORGAN; VASCULAR DISEASE;

BLOOD COAGULATION DISORDERS; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; RISK FACTORS; VASCULAR DISEASES;

EID: 0037710252     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376-86.
2. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996;27:978-90.
3. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130:933-7.
4. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
5. Lip GY. Fibrinogen and cardiovascular disorders. Q J Med 1995;88:155-65.
6. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
7. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6.
8. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-55.
9. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-44.
10. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y et al. A 6 year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992;68:261-3.
11. Baxter K, Wiseman S, Powell J, Greenhalgh R. Pilot study of a screening test for peripheral arterial disease in middle aged men: fibrinogen as a possible risk factor. Cardiovasc Res 1988;22:300-2.
12. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987;317:521-6.
13. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993;69:338-42.
14. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-88.
15. Makris TK, Tsoukala C, Krespi P, Hatzizacharias A, Gialeraki A, Papargyriou J et al. Haemostasis balance disorders in patients with essential hypertension. Thromb Res 1997;88:99-107.
16. Donders SH, Lustermans FA, Van Wersch JW. Coagulation factors and lipid composition of the blood in treated and untreated hypertensive patients. Scand J Clin Lab Invest 1993;53:179-86.
17. Cigolini M, Targher G, Seidell JC, Tonoli M, Schiavon R, Agostino G et al. Relationships of blood pressure to fibrinolysis: influence of anthropometrymetabolic profile and behavioural variables. J Hypertens 1995;13:659-66.
18. Lowe GD, Wood DA, Douglas JT, Riemersma RA, Macintyre CC, Takase T et al. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost 1991;65:339-43.
19. Smith WCS, Lowe GDO, Lee AJ, Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens 1992;10:467-72.
20. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000;36:978-85.
21. Organization-International Society of Hypertension: Guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
22. von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.
23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
24. De Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995;25:1056-62.
25. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87:1107-13.
26. American Diabetes Association: Report of the Expert Committee on the dignosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-201.
27. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997;17:1539-44.
28. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
29. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
30. Folsom AR, Peacock JM, Nieto J, Rosamond WD, Eigenbrodt ML, Davis CE et al. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study J Hypertens 1998;16:1579-83.
31. Chambless LE, Folsom AR, Davis V, Sharret R, Heiss G, Sorlie P et al. Risk Factors for Progression of Common Carotid Atherosclerosis: The Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2002;155:38-47.
32. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102: 1634-8.
33. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk on cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672-6.
34. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996;45:954-9.
35. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
36. Junker R, Heinrich J, Schulte H, Erren M, Assmann G. Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Munster study. J Hypertens 1998;16:917-23.
37. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000;101:264-9.